Cabazitaxel NEW
| Price | $50 |
| Package | 1mL |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: Cabazitaxel | CAS No.: 183133-96-2 |
| Purity: ≥95% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | Cabazitaxel |
| Description | Cabazitaxel (taxoid XRP6258) is a taxane and antineoplastic agent which is currently used in the therapy of castration-resistant metastatic prostate cancer after failure of docetaxel. |
| Cell Research | The cytotoxicity of CBX-loaded ANs and free Cabazitaxel (CBX) is evaluated with MTT assay. Cells are seeded onto a 96-well plate at a density of 3000 cells per well and cultured for 24 h. CBX-loaded ANs and free CBX are diluted to predetermined concentrations with PBS and added into each well. Blank AN, AN-ICG and free CBX solvent (a mixture of Tween-80 and anhydrous alcohol) are added as well to different final concentrations. The incubation continued for another 48 hours. 20 μL MTT solutions (5 mg/mL in PBS) are added into each well and cells are incubated for another 4 hours under 37°C. Subsequently the medium is removed and 150 μL dimethyl sulphoxide (DMSO) is added to dissolve the purple formazan salt crystals. Then the absorbance is measured by a microplate reader at 490 nm. The cells treated with medium are evaluated as controls. |
| In vitro | In situ and subcutaneous mouse xenografts were generated using SF-295 and U251 human glioblastoma cell lines. Treatment with Cabazitaxel resulted in the complete regression of the majority of subcutaneously implanted tumors. Cabazitaxel also demonstrated significant antitumor activity in other related models. Specifically, Cabazitaxel led to complete tumor regression in mouse tumor xenograft models (colon C38 and pancreatic P03). Moreover, in the in situ model, Cabazitaxel caused complete regression in 4 out of 10 U251 tumors. |
| In vivo | Cabazitaxel has an average in vitro human plasma protein binding rate of 91.6%. It is rapidly and extensively metabolized into various metabolites. Cabazitaxel exhibits activity in multiple resistant cell lines in both mice and humans, and it increases the enzymatic activity of CYP3A in rat liver cells. Additionally, Cabazitaxel demonstrates high antitumor activity in three colon cancer cell lines (HCT-116, HCT-8, and HT-29). Treating with relatively low concentrations of Cabazitaxel for four days results in significant cytotoxicity. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | H2O : < 1 mg/mL (insoluble or slightly soluble) Ethanol : < 1 mg/mL (insoluble or slightly soluble) DMSO : 93 mg/mL (111.3 mM) |
| Keywords | Microtubule/Tubulin | Autophagy | inhibit | taxoid XRP-6258 | XRP-6258 | XRP 6258 | Cabazitaxel | TXD-258 | TXD258 | taxoid XRP 6258 | Inhibitor |
| Inhibitors Related | Hydroxychloroquine | Guanidine hydrochloride |
| Related Compound Libraries | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | FDA-Approved Drug Library | Anti-Cancer Approved Drug Library | Anti-Aging Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-09-05 | |
| $10.70/1kg |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-20 | |
| $0.00/1kg |
VIP1Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-04-30 | |
| $0.00/25kg |
Shaanxi Haibo Biotechnology Co., Ltd
|
2023-09-07 | ||
| $50.00/1kg |
Henan Bao Enluo International TradeCo.，LTD
|
2023-08-16 | ||
| $0.00/1kg |
VIP2Y
|
Hangzhou ICH Biofarm Co., Ltd
|
2023-06-26 | |
| $0.00/1Kg |
VIP3Y
|
Changzhou Rokechem Technology Co., Ltd.
|
2023-06-21 | |
| $0.00/1g |
VIP4Y
|
WUHAN FORTUNA CHEMICAL CO., LTD
|
2021-07-27 | |
| $15.00/1KG |
Zhuozhou Wenxi import and Export Co., Ltd
|
2021-07-10 | ||
| $1.10/1g |
VIP4Y
|
Shaanxi Dideu Medichem Co. Ltd
|
2021-05-26 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY